FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1676-1678 April 15, 2004 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Perspective by Liu, E. T. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bullinger, L. Related Article by Valk, P. J.M. PubMed Citation

The past three decades have seen considerable advances in our understanding of the underlying mechanisms of acute myeloid leukemia (AML) and dramatic improvements in treatment. At present, decisions about therapy are largely based on prognostic factors identified at the time of diagnosis or shortly thereafter. These features include age, the karyotype of the leukemic clone, the initial leukocyte count, and the response to induction chemotherapy. Karyotypic analysis is particularly important, because it not only provides a key prognostic indicator but also serves to identify biologically distinct subgroups of AML, which in some instances require specific types of treatment.¹ All-trans. . . [Full Text of this Article]

Source Information

From the Department of Medical and Molecular Genetics, Guy's, King's and St. Thomas' School of Medicine, and the Department of Haematology, University College London Hospitals — both in London (D.G.); and the Laboratory for Leukemia Diagnostics, Medical Department III, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany (T.H.).

This article has been cited by other articles:

• Sakhinia, E, Farahangpour, M, Tholouli, E, Liu Yin, J A, Hoyland, J A, Byers, R J (2006). Comparison of gene-expression profiles in parallel bone marrow and peripheral blood samples in acute myeloid leukaemia by real-time polymerase chain reaction. J. Clin. Pathol. 59: 1059-1065 [Abstract] [Full Text]  
• Monzo, M., Brunet, S., Urbano-Ispizua, A., Navarro, A., Perea, G., Esteve, J., Artells, R., Granell, M., Berlanga, J., Ribera, J. M., Bueno, J., Llorente, A., Guardia, R., Tormo, M., Torres, P., Nomdedeu, J. F., Montserrat, E., Sierra, J., for CETLAM, (2006). Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 107: 4871-4879 [Abstract] [Full Text]  
• Tallman, M. S., Gilliland, D. G., Rowe, J. M. (2005). Drug therapy for acute myeloid leukemia. Blood 106: 1154-1163 [Abstract] [Full Text]  
• Haferlach, T., Kohlmann, A., Schnittger, S., Dugas, M., Hiddemann, W., Kern, W., Schoch, C. (2005). Global approach to the diagnosis of leukemia using gene expression profiling. Blood 106: 1189-1198 [Abstract] [Full Text]  
• (2004). Gene-Expression Profiling Predicts Prognosis of AML. JWatch General 2004: 2-2 [Full Text]